Nevertheless, these observations suggest testable hypotheses for the response of “PD-L1-negative” cancers to immunotherapeutics—that IHC negative tumors may contain functionally competent PD-L1 that is significantly N-glycosylated and therefore not detectable by some antibodies. The gene discussed is CD274; the disease is cancer.